Metastatic Pancreatic CancerPhase 1NCT06538207
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
A Phase 1 study testing ONO-4578, ONO-4538 and Oxaliplatin in people with Metastatic Pancreatic Cancer, run by Ono Pharmaceutical Co., Ltd. at 9 sites in Japan.
Trial summary
This study is a multicenter, open-label, uncontrolled study to investigate the tolerability and safety of ONO-4578, ONO-4538, and standard of care in combination as first-line treatment in patients with metastatic pancreatic cancer. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Metastatic Pancreatic Cancer
- What is being tested?
- ONO-4578, ONO-4538 and Oxaliplatin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 9 sitesJapan
- Study dates
- 13 Jan 2021to 30 Jan 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Pancreatic invasive ducatal adenocarcinoma
- 2. Life expectancy of at least 3 months
- 3. Patients with ECOG performance status 0 or 1
Who cannot join
- 1. Patients with severe complication
- 2. Patients with multiple primary cancers
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
Japan9 sites
Juntendo University Hospital
Bunkyō-Ku, Tokyo
The University of Tokyo Hospital
Bunkyō-Ku, Tokyo
National Cancer Center Hospital
Chuo Ku, Tokyo
Seirei Hamamatsu General Hospital
Hamamatsu, Shizuoka
National Cancer Center Hospital East
Kashiwa-shi, Chiba
The Cancer Institute Hospital of JFCR
Koto-Ku, Tokyo
Kyorin University Hospital
Mitaka-shi, Tokyo
Keio University Hospital
Shinjuku-Ku, Tokyo
Kanagawa Cancer Center
Yokohama, Kanagawa
About this study
This study is a multicenter, open-label, uncontrolled study to investigate the tolerability and safety of ONO-4578, ONO-4538, and standard of care in combination as first-line treatment in patients with metastatic pancreatic cancer.
- Conditions
- Metastatic Pancreatic Cancer
- Being tested
- ONO-4578, ONO-4538, Oxaliplatin, Levofolinate, Irinotecan
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ONO-4578Drug
Specified dose on specified days
ONO-4538Drug
Also called Nivolumab
Specified dose on specified days
OxaliplatinDrug
Specified dose on specified days
LevofolinateDrug
Specified dose on specified days
IrinotecanDrug
Specified dose on specified days
FluorouracilDrug
Specified dose on specified days
GemcitabineDrug
Specified dose on specified days
Nab-PaclitaxelDrug
Specified dose on specified days
| Study group | Role | What they receive |
|---|---|---|
| ONO-4578+ONO-4538+mFFX | Experimental | Not described Receives: Drug: ONO-4578; Drug: ONO-4538; Drug: Oxaliplatin; Drug: Levofolinate; Drug: Irinotecan; Drug: Fluorouracil |
| ONO-4578+ONO-4538+GnP | Experimental | Not described Receives: Drug: ONO-4578; Drug: ONO-4538; Drug: Gemcitabine; Drug: Nab-Paclitaxel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose-limiting toxicities（DLT）
Measured: 28 days
Adverse event(AE)
Measured: UP to 28 days after the last dose
Secondary outcomes (12)
Pharmacokinetics (Plasma concentration for ONO-4578)
Measured: Up to 28 days after the last dose
Pharmacokinetics (Serum concentration for ONO-4538)
Measured: Up to 28 days after the last dose
Overall response rate (ORR)
Measured: Up to 2 years
Disease control rate (DCR)
Measured: Up to 2 years
Overall survival (OS)
Measured: Up to 2 years
Progression-free survival (PFS)
Measured: Up to 2 years
Duration of response (DOR)
Measured: Up to 2 years
Time to response (TTR)
Measured: Up to 2 years
Best overall response (BOR)
Measured: Up to 2 years
Percentage of change in the sum of tumor diameters of target lesions
Measured: Up to 2 years
Maximum percentage of change in the sum of tumor diameters of target lesions
Measured: Up to 2 years
Changes in tumor markers (CEA and CA19-9)
Measured: Up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2024
- Study start13 Jan 2021
- Primary completion1 Oct 2024
- Study completion30 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metastatic Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by Ono Pharmaceutical Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Project Leader, Study director, Ono Pharmaceutical Co., Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06538207
- Sponsor's protocol ID
- ONO-4578-04
- Other IDs
- jRCT2031200286
- Status last verified
- Feb 2025
- First submitted
- 29 Jul 2024
- Last updated
- 6 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- ClinicalTrials.gov ID
- NCT06538207
- Acronym / sponsor ID
- ONO-4578-04
- Conditions
- Metastatic Pancreatic Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants (actual)
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 13 Jan 2021 (actual)
- Primary completion
- 1 Oct 2024 (actual)
- Study completion
- 30 Jan 2025 (actual)
- First posted
- 5 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a multicenter, open-label, uncontrolled study to investigate the tolerability and safety of ONO-4578, ONO-4538, and standard of care in combination as first-line treatment in patients with metastatic pancreatic cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ONO-4578+ONO-4538+mFFX | Experimental | Drug: ONO-4578, Drug: ONO-4538, Drug: Oxaliplatin, Drug: Levofolinate, Drug: Irinotecan, Drug: Fluorouracil |
| ONO-4578+ONO-4538+GnP | Experimental | Drug: ONO-4578, Drug: ONO-4538, Drug: Gemcitabine, Drug: Nab-Paclitaxel |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- 1. Pancreatic invasive ducatal adenocarcinoma
- 2. Life expectancy of at least 3 months
- 3. Patients with ECOG performance status 0 or 1
Key exclusion criteria (2 listed)
- 1. Patients with severe complication
- 2. Patients with multiple primary cancers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ONO-4578Specified dose on specified days | Drug | ONO-4578+ONO-4538+GnP, ONO-4578+ONO-4538+mFFX |
| ONO-4538Also: NivolumabSpecified dose on specified days | Drug | ONO-4578+ONO-4538+GnP, ONO-4578+ONO-4538+mFFX |
| OxaliplatinSpecified dose on specified days | Drug | ONO-4578+ONO-4538+mFFX |
| LevofolinateSpecified dose on specified days | Drug | ONO-4578+ONO-4538+mFFX |
| IrinotecanSpecified dose on specified days | Drug | ONO-4578+ONO-4538+mFFX |
| FluorouracilSpecified dose on specified days | Drug | ONO-4578+ONO-4538+mFFX |
| GemcitabineSpecified dose on specified days | Drug | ONO-4578+ONO-4538+GnP |
| Nab-PaclitaxelSpecified dose on specified days | Drug | ONO-4578+ONO-4538+GnP |
Primary outcome
Dose-limiting toxicities（DLT）
Time frame: 28 days
Adverse event(AE)
Time frame: UP to 28 days after the last dose
12 secondary outcomes
Pharmacokinetics (Plasma concentration for ONO-4578)
Time frame: Up to 28 days after the last dose
Pharmacokinetics (Serum concentration for ONO-4538)
Time frame: Up to 28 days after the last dose
Overall response rate (ORR)
Time frame: Up to 2 years
Disease control rate (DCR)
Time frame: Up to 2 years
Overall survival (OS)
Time frame: Up to 2 years
Progression-free survival (PFS)
Time frame: Up to 2 years
Duration of response (DOR)
Time frame: Up to 2 years
Time to response (TTR)
Time frame: Up to 2 years
Best overall response (BOR)
Time frame: Up to 2 years
Percentage of change in the sum of tumor diameters of target lesions
Time frame: Up to 2 years
Maximum percentage of change in the sum of tumor diameters of target lesions
Time frame: Up to 2 years
Changes in tumor markers (CEA and CA19-9)
Time frame: Up to 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Metastatic Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer, Pancreatic Cancer Metastatic
Recruiting
CREO - Microwave Ablation Feasibility Study
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Project Leader study director
Ono Pharmaceutical Co., Ltd.
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ONO-4578, ONO-4538 and Oxaliplatin in people with Metastatic Pancreatic Cancer, run by Ono Pharmaceutical Co., Ltd. at 9 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dose-limiting toxicities（DLT） (time frame: 28 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2025.